UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
This piece offers concrete examples of price, market-cap, and equal weighting schemes, illustrating how each affects index composition and risk.
4,740 articlesThree clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Nebius surges on a pair of cloud deals and a swelling backlog, but a late Q4 miss and execution doubts keep investors...
U.S. stocks drifted midweek as analysts rolled out fresh price targets on key names. Here’s a look at Wednesday’s top...
As geopolitical shocks push oil prices around, crypto traders turn hyperliquid venues to pursue oil-based bets. Learn...
Income-focused ETFs can deliver higher yields, but they often cap upside and introduce new risks. This guide breaks d...
International markets are shining again. This article breaks down why VYMI could be a smart addition for income-focus...
Gig life offers freedom, but retirement planning can feel far off. Here are five practical, real-world strategies to ...
Headline rent figures hide true costs faced by tenants. This piece explains why the 'average rent' mirage misleads, a...
Archer Aviation aims to redefine urban mobility, but a crowded risk landscape could derail the bull case. This deep d...
The White House announced a temporary waiver of the Jones Act to boost crude shipments between U.S. ports. Early mark...
As volatility rises and headlines loom, investors ask: is the S&P 500 headed correction? This guide breaks down what ...
Shay Capital reduced its PureCycle stake in the latest 13F filing, prompting questions about the stock's future. This...